4D Molecular Therapeutics (FDMT) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed 4D Molecular Therapeutics (FDMT) over the past year, gaining 232.1% versus a gain of 51.3%. 4D Molecular Therapeutics is the larger company by market cap ($695.5 million vs $662.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FDMT | NVCT |
|---|---|---|
| Share price | $12.59 | $20.29 |
| Market cap | $695.52M | $662.35M |
| 1-day change | +0.24% | +1.30% |
| YTD return | +67.87% | +168.74% |
| 1-year return | +51.32% | +232.08% |
| 5-year return | -53.92% | — |
| EPS (TTM) | $-2.63 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.93 | $29.28 |
| 52-week low | $6.96 | $5.55 |
| Distance from 52-week high | -25.63% | -30.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +123.11% | +74.47% |
| Average volume | 924.05K | 217.91K |
| Shares outstanding | 55.24M | 32.64M |
| Employees | 196 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed FDMT by 180.8 percentage points over the past year.
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
FDMT vs NVCT FAQ
Which is bigger, 4D Molecular Therapeutics or Nuvectis Pharma?
4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $695.52M compared with $662.35M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, FDMT or NVCT?
NVCT returned +232.08% over the past 12 months, compared with +51.32% for FDMT (price return, excluding dividends). Past performance does not predict future results.
Are 4D Molecular Therapeutics and Nuvectis Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for 4D Molecular Therapeutics and Biotechnology: Pharmaceutical Preparations for Nuvectis Pharma.